Biosimilar Labeling: US FDA’s Final Guidance Means Status Quo For Sponsors
Executive Summary
Advice document, little changed from a March 2016 draft, continues to reflect agency’s view that clinical studies supporting a demonstration of biosimilarity should not be included in labeling.
You may also be interested in...
With Interchangeability Nod, Viatris' Semglee Loses Its Identity
Now approved as an interchangeable biosimilar, US labeling for Viatris’ insulin aspart mirrors that of Sanofi’s Lantus and has shed data from two studies in type 1 and 2 diabetics that showed noninferiority to Sanofi’s Lantus; Viatris appears in line for one year of exclusivity.
Biosimilar Action Packages Low On US FDA Priority List For Redaction And Posting
Final review documents have been posted for only four of 12 biosimilars due to a backlog in applications considered the third priority level for redaction – a categorization that seems out of sync with the agency’s approach to labeling and its emphasis on promoting price competition.
Biosimilar Action Packages Low On US FDA Priority List For Redaction And Posting
Final review documents have been posted for only four of 12 biosimilars due to a backlog in applications considered the third priority level for redaction – a categorization that seems out of sync with the agency’s approach to labeling and its emphasis on promoting price competition.